Publication | Closed Access
TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
54
Citations
0
References
2012
Year
Surgical OncologyCancer ManagementPathologyPharmacotherapySecond-line TreatmentOncologyPhase Iii TrialClinical TrialsClinical OncologyRadiation OncologyNovel TherapyCancer ResearchMolecular OncologyFinal TextHealth SciencesAsco Daily NewsCancer TreatmentMalignant DiseaseTumoral PathologyNsclc PatientsMedicine
LBA7501 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.